"Would it make any difference seeing that apabetalone had very little to no effect in the BOM clinical trial study as noted below?"
I think you are missing the point Koo. I believe Barsax was getting at what additional benefical CNS effects would apabetalone have if it could get across the BBB more efficiently with assistance from a carrier like xB3.
BDAZ